|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.10.25 - 14:06
|
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO Phase II trial were shared in a Proffered Paper oral presentation by Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the 2025 European Society of Medical Oncology (ESMO) Congress in Berlin, Germany....
|
|
|
09.10.25 - 14:03
|
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a patient enrolment update for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as first line treatment for advanced or metastatic non-small cell lung cancer (1L NSCLC)....
|
|
|
10.09.25 - 06:45
|
Biotech Stocks Rally After-Hours On Trial Updates, Insider Buys, And Conference Buzz (RTTNews)
|
|
|
Biotech stocks lit up the after-hours session on September 9, 2025, with several small- and mid-cap names posting sharp gains following fresh clinical updates, insider buying, and investor conference appearances. Companies like Immutep, Nautilus Biotechnology, Pliant Therapeutics, Phio Pharmaceuticals, and Kura Oncology all saw renewed momentum, driven by near-term catalysts that are drawing ......
|
|
|
|
|
|
|
|
|
28.07.25 - 11:15
|
XFRA: SPAFR - HANDELSUNTERBRECHUNG IN DIVERSEN AUSLANDSAKTIEN - TEIL 6 (XETRA)
|
|
|
AU000000ALQ6
AU000000ARL4
AU000000ARV3
AU000000AUC7
AU000000AZJ1
AU000000BAP9
AU000000BCT7
AU000000BEN6
AU000000BRK4
AU000000BSX5
AU000000BVS9
AU000000CAA9
AU000000CAV5
AU000000CCV1
AU000000CLZ3
AU000000CMM9
AU000000CNJ3
AU000000COB8
AU000000CTD3
AU000000CWY3
AU000000CXM6
AU000000CXO2
AU000000DEM4
AU000000DOW2
AU000000DTL4
AU000000DTZ4
AU000000EOL3
AU000000EVN4
AU000000EZL9
AU000000FBR4
AU000000FPC6
AU000000GBZ5
AU000000GEM7
AU000000GOZ8
AU000000HAS0
AU000000HLO6
AU000000HRN5
AU000000HSN3
AU000000IMA1
AU000000IMM6
AU000000JAT4
AU000000KAI5
AU000000LIT3
AU000000LYC6
AU000000MCP2
AU000000MDI5
AU000000MEM5
AU000000MGR9
AU000000MGX7
AU000000MMI6
AU000000MMS5
AU000000MRC8
AU000000MTC4
AU000000NUF3
AU000000NXT8
AU000000ODY8
AU000000PDN8
AU000000PEK2
AU000000PGY8
AU000000PME8
AU000000PNR8
AU000000PNV0
AU000000PTL8
AU000000RCE5
AU000000REA9
AU000000REX1
AU000000RGL1
AU000000RIC6
AU000000RMD6
AU000000SCG8
AU000000SER1
AU000000SGP0
AU000000SGQ8...
|
|
|
|
|
27.05.25 - 14:03
|
Immutep′s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded the study's prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectable soft tissue sarcoma (STS)....
|
|
|
15.05.25 - 05:36
|
Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial (Small Caps)
|
|
|
Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The assessment of eftilagimod alpha (efti) with Keytruda and chemotherapy has achieved high response rates in the multi-centre INSIGHT-003 trial, an investigator-initiated study conducted by […]
The post Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial appeared first on Small Caps....
|
|
|
05.05.25 - 06:01
|
Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial (Small Caps)
|
|
|
Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase IIb trial to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). The study, which evaluated eftilagimod alfa (efti) in combination with anti-PD-1 therapy Keytruda (pembrolizumab) as first-line therapy for […]
The post Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial appeared first on Small Caps....
|
|
|
|
|
02.04.25 - 14:03
|
Immutep to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
